Videos

Blood-based biomarkers are helping clinicians move past vague dementia diagnoses, but an expert says the tests belong only after a full workup in patients with objective impairment.

Christoph U. Correll, MD, says prescriber discomfort, more than patient factors, drives low LAI use in schizophrenia, and urges clinicians to present injectables as support for autonomy.

Anita Clayton, MD, explains how anhedonia points to past trauma and to future suicide and relapse risk, and how clinicians can screen for it quickly.

Christoph Correll, MD, explains why asking "How many doses have you missed?" works better than "Are you taking your medication?" and how to address the reasons behind missed doses.

An esketamine expert reflects on 7 years of nasal spray use and asks why racemic ketamine faces none of the same rules.

Explore tailored MDD augmentation strategies, balancing antipsychotic side effects, cautious dosing in older adults, and when to consider ketamine after partial response.

Why psychiatry might miss daytime sleepiness; assess sleep debt, scale scores, and sedating meds, deprescribe wisely, and rule out sleep apnea before stimulants.

Real-world data show Lybalvi cuts acute care visits in schizophrenia or bipolar I with AUD, while long-acting aripiprazole offers flexible dosing and stable symptom control.

Longer follow-up and real-world claims data add context that pivotal trials alone cannot provide. The panel examines both, alongside how monitoring for response actually happens in daily practice.

A second on-label option carries its own distinct mechanism and its own trial history. The panel details how this antipsychotic therapy was studied and what its data actually show.

Fear of losing custody, self-blame, and not knowing the condition is treatable keep mothers silent. Clinicians can address each one directly.

Postpartum psychosis is a psychiatric emergency with a fluctuating, atypical presentation and a high risk of recurrence that clinicians can easily miss.

SAINT neuromodulation rapidly eases severe depression, enabling therapy and recovery in days; personalized targeting boosts outcomes, while access grows and suicide data remains limited.

Learn how antipsychotic blood levels guide dosing, spot nonadherence, and set clozapine/haloperidol targets for better schizophrenia outcomes.

SAINT uses brain imaging-guided TMS to deliver rapid, intensive sessions, helping treatment-resistant depression patients reach remission faster than conventional protocols.

Ketogenic nutrition and insulin-targeted metabolic psychiatry may add a new tool for severe mental illness.

Learn why ketogenic metabolic therapy is a monitored medical treatment, not a fad diet, and how metabolic pathways may reshape mental health care.

Many symptoms that most impair patients with major depressive disorder go unspoken until treatment starts working, making early recognition and patient-defined goals central to effective care.

How insulin resistance, inflammation, and ketogenic therapy reshape treatment for bipolar and schizophrenia—inside the rise of metabolic psychiatry.

Depression's cardinal symptoms are often invisible to the patient reporting them. Dr. Harding and Dr. Citrome examine why diagnosis, not treatment, remains psychiatry's hardest task, and how family observation and screening for bipolar depression change the diagnostic path.

New evidence links hippocampal “internally generated” activity to memory and psychosis, suggesting new network-based models for schizophrenia.

Hippocampal “tuplets” build predictive sequences; sleep rapidly rewires schemas for insight learning, offering clues to schizophrenia hallucinations.

Extended-release stimulants have become first-line therapy for adult ADHD, replacing outdated practices that once set patients up for failed medication trials. The panel explains why.

Deciding when and how to change a schizophrenia treatment plan requires curiosity, comparative evidence, and careful sequencing. The panel discusses long-acting injectables, combination strategies, and when clozapine becomes the right next step.

From long-acting injectables to rational combination therapy, the panel maps today's treatment landscape, weighing efficacy against adverse events and stressing the

ADHD rarely confines itself to one area of an adult's life. The panel traces how the condition's burden compounds across work, family, and relationships as responsibilities grow.

Xanomeline-trospium targets muscarinic receptors for schizophrenia relief with fewer side effects, and early data suggest cognitive gains.

Cobenfy revived shelved muscarinic therapy for schizophrenia, easing side effects while boosting negative and cognitive symptoms across trials.

Most depression in this country is never treated by a psychiatrist. The panel maps which parts of the journey primary care can own, where handoffs break down, and what safety demands first.

The imaging evidence is associational, not causal. The panel weighs whether that is reason enough for a skeptical colleague to treat depression earlier, and how anxiety complicates the picture.